Sally C. Pipes

Commentary

Hospitals must be more transparent about health care costs

Some Illinois hospitals are keeping their prices secret from their patients. Only three out of a sample of 11 major medical facilities in the state are fully compliant with a federal rule requiring hospitals to publish the costs of common services, according to data from the nonprofit group PatientsRightsAdvocate.org. That includes hospitals ...
Commentary

Drug price controls would limit new medicines

The Democrats’ budget reconciliation bill is winding its way through the Senate. Last week, Republican and Democratic senators met with the chamber’s parliamentarian to discuss whether the bill’s proposal for Medicare to negotiate the price of prescription drugs with manufacturers has a direct impact on government spending or tax revenue, as reconciliation ...
Commentary

Dems’ Reconciliation Bill Would Push US Economy Over Cliff

Inflation is at its highest level in four decades, according to federal data out last week. Senate Democrats say they have a solution — their newly revamped budget reconciliation bill, which would levy price controls on prescription drugs and provide billions in subsidies for health insurance sold through Obamacare’s exchanges. How this proposal ...
Commentary

Stop funneling more money toward failing Affordable Care Act

Democrats in Congress are scrambling to extend the enhanced Obamacare subsidies signed into law by President Biden last year as part of the American Rescue Plan Act. It’s no mystery why. If lawmakers allow these premium tax credits to expire — as they’re set to at the end of this year — ...
Commentary

It’s Time To Cure The FDA’s Regulatory Sclerosis

Late last month, the Food and Drug Administration advised COVID-19 vaccine manufacturers to develop booster shots aimed at the omicron variant of the virus. Regulators hope the shots will be ready by the fall. That will probably be too late to stop BA.5, the highly transmissible subvariant that has quickly become the dominant strain in ...
Commentary

Improving Access to Paxlovid Long Overdue

The following op-ed has been authored by a non-clinician, it does not constitute medical advice. In an effort to boost access to the antiviral Paxlovid, the Food and Drug Administration (FDA) will now allow pharmacists to prescribe the medicine; the agency announced this last week, on July 6. Previously, patients seeking the ...
Commentary

‘Build Back Better’ would tear down patients’ hope for better medicines

Congressional Democrats are working to revive the multi-trillion-dollar spending package once dubbed “Build Back Better.” They intend to finance this wave of spending in part by siphoning money away from life-saving research on diseases like cancer, heart disease, and Alzheimer’s. That would be the chief consequence of a widely-discussed provision ...
Commentary

New price transparency rule will help patients

This month, a federal rule requiring certain private health plans to disclose the rates they pay providers for covered healthcare services takes effect. The Trump-era regulation, along with a similar rule requiring hospitals to publish their prices, is an example of the previous administration’s drive to make the healthcare system more transparent. Such transparency ...
Commentary

New price transparency rule will help patients

This month, a federal rule requiring certain private health plans to disclose the rates they pay providers for covered healthcare services takes effect. The Trump-era regulation, along with a similar rule requiring hospitals to publish their prices, is an example of the previous administration’s drive to make the healthcare system more transparent. Such transparency ...
Commentary

Nothing Curative About Dems Inflation, Higher Taxes and Prices

Congressional Democrats are one step closer to passing their trillion-dollar “Build Back Better” spending package. On July 6 U.S. Senate leaders hashed out a key proposal that would allow Medicare to “negotiate” with pharmaceutical companies over prescription drug prices. The effort is part of Senate Majority Leader Charles Schumer’s, D- N.Y., drive ...
Commentary

Hospitals must be more transparent about health care costs

Some Illinois hospitals are keeping their prices secret from their patients. Only three out of a sample of 11 major medical facilities in the state are fully compliant with a federal rule requiring hospitals to publish the costs of common services, according to data from the nonprofit group PatientsRightsAdvocate.org. That includes hospitals ...
Commentary

Drug price controls would limit new medicines

The Democrats’ budget reconciliation bill is winding its way through the Senate. Last week, Republican and Democratic senators met with the chamber’s parliamentarian to discuss whether the bill’s proposal for Medicare to negotiate the price of prescription drugs with manufacturers has a direct impact on government spending or tax revenue, as reconciliation ...
Commentary

Dems’ Reconciliation Bill Would Push US Economy Over Cliff

Inflation is at its highest level in four decades, according to federal data out last week. Senate Democrats say they have a solution — their newly revamped budget reconciliation bill, which would levy price controls on prescription drugs and provide billions in subsidies for health insurance sold through Obamacare’s exchanges. How this proposal ...
Commentary

Stop funneling more money toward failing Affordable Care Act

Democrats in Congress are scrambling to extend the enhanced Obamacare subsidies signed into law by President Biden last year as part of the American Rescue Plan Act. It’s no mystery why. If lawmakers allow these premium tax credits to expire — as they’re set to at the end of this year — ...
Commentary

It’s Time To Cure The FDA’s Regulatory Sclerosis

Late last month, the Food and Drug Administration advised COVID-19 vaccine manufacturers to develop booster shots aimed at the omicron variant of the virus. Regulators hope the shots will be ready by the fall. That will probably be too late to stop BA.5, the highly transmissible subvariant that has quickly become the dominant strain in ...
Commentary

Improving Access to Paxlovid Long Overdue

The following op-ed has been authored by a non-clinician, it does not constitute medical advice. In an effort to boost access to the antiviral Paxlovid, the Food and Drug Administration (FDA) will now allow pharmacists to prescribe the medicine; the agency announced this last week, on July 6. Previously, patients seeking the ...
Commentary

‘Build Back Better’ would tear down patients’ hope for better medicines

Congressional Democrats are working to revive the multi-trillion-dollar spending package once dubbed “Build Back Better.” They intend to finance this wave of spending in part by siphoning money away from life-saving research on diseases like cancer, heart disease, and Alzheimer’s. That would be the chief consequence of a widely-discussed provision ...
Commentary

New price transparency rule will help patients

This month, a federal rule requiring certain private health plans to disclose the rates they pay providers for covered healthcare services takes effect. The Trump-era regulation, along with a similar rule requiring hospitals to publish their prices, is an example of the previous administration’s drive to make the healthcare system more transparent. Such transparency ...
Commentary

New price transparency rule will help patients

This month, a federal rule requiring certain private health plans to disclose the rates they pay providers for covered healthcare services takes effect. The Trump-era regulation, along with a similar rule requiring hospitals to publish their prices, is an example of the previous administration’s drive to make the healthcare system more transparent. Such transparency ...
Commentary

Nothing Curative About Dems Inflation, Higher Taxes and Prices

Congressional Democrats are one step closer to passing their trillion-dollar “Build Back Better” spending package. On July 6 U.S. Senate leaders hashed out a key proposal that would allow Medicare to “negotiate” with pharmaceutical companies over prescription drug prices. The effort is part of Senate Majority Leader Charles Schumer’s, D- N.Y., drive ...
Scroll to Top